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Review      
Mandatory multidisciplinary approach for the 
evaluation of the lymph node status in rectal 
cancer  
 Marian Diaconescu1, Cosmin V. Obleaga1, Cecil S. Mirea1, Mihai C. Ciorbagiu1, 
Emil Moraru1, Ionica D. Vilcea1  
 1Craiova University of Medicine and Pharmacy, Department of General Surgery, Craiova, Romania 
Abstract        Colorectal cancer is the third most frequently reported malignancy and also the third leading 
cancer-related cause of death worldwide. Lymph node evaluation, both preoperatively and 
postoperatively, represents an important aspect of the diagnosis and therapeutic strategy in 
colorectal cancer, such that an accurate preoperative staging is required for a correct therapeutic 
strategy. Treatment of rectal cancer with positive lymph nodes, a very important predictive 
prognostic parameter, is currently based on neoadjuvant chemoradiotherapy followed by total/ 
surgical mesorectal excision and adjuvant regimen. 
      Preoperative evaluation of the lymph node status in rectal cancer is based on endoscopic 
ultrasound and magnetic resonance imaging, but their accuracy, specificity, and sensitivity still 
require improvement. Postoperative evaluation also presents points of debate, especially related 
to the role of sentinel lymph node mapping and their final implication, represented by detection 
of micrometastases and isolated tumor cells. The pathologic interpretation of tumor deposits 
represents other points in discussion. From a surgical perspective, extended lateral lymph node 
dissection vs. abstinence and (neo)adjuvant therapeutic approach represent another unresolved 
issue. 
       This review presents the major controversies existing today in the treatment and pathologic 
interpretation of the lymph nodes in rectal cancer, the role/ indication and value of the lateral 
pelvic lymph node dissection, and the postoperative interpretation of the value of the 
micrometastatic disease and tumor deposits. 
 
Keywords  rectal cancer, lymph node evaluation, lateral lymph node dissection, sentinel lymph node 
mapping, micrometastases 
Highlights ✓ Despite important progress made in the evaluation and prognostic interpretation of 
lymph nodes in rectal cancer, many controversial and unresolved aspects remain, 
requiring future clarification.  
✓ An accurate interpretation requires better standardization than is now offered by 
current staging systems, as suggested in this review.    




Colorectal cancer is the third most common 
malignancy reported at all sites, for both sexes, and also 
the third leading cancer-related cause of death (1-3). The 
incidence of rectal cancer in USA is about 12.3% per 
100,000 people, with an estimated 39,610 new cases in 
2015 (1, 4). Rectal topography represents between 17-
41% of the colorectal cancer cases, depending on the 
patient’s age and sex (the proportion is higher in younger 
patients and in men). Almost 33% of the rectal cancers 
will have regional spread at the time of the diagnosis, 
associated with a 5-year relative survival rate of 69.5% 
(4). The T stage and high-grade pathology represent the 
most important independent predictive factors for the 
risk of lymph node involvement (5).  
Lymph node involvement represents one of the most 
important predictive parameters for survival: the 5-year 
overall survival rates varies significantly from 74% if 
nodal spread is absent (N0), to 64% if only 1-3 lymph 
nodes are invaded (N1), and drops to 48% if more than 4 
lymph nodes are invaded (N2); at the same time the local 
recurrence rates will significantly increase from 9% if 
N0, to 11% if N1, and 13% if N2 (6). 
The treatment of rectal cancer with positive lymph 
nodes is based in most centers on neoadjuvant 
chemoradiotherapy, followed by rectal resection with 
total mesorectal excision and adjuvant regimen. Some 
centers apply extended lateral lymph nodes dissection. 
Adequate treatment is based on the correct preoperative 
evaluation of the lymph nodes basin which can be 
influenced by many factors. The significance of an 
adequate evaluation of the lymph node status in rectal 
cancer is emphasized by the SEER analysis results that 
show important declines in the 5-year relative survival 
rates in cases with incorrect evaluation of the lymph 
nodes (Nx): 23.8-89.4%, almost similar with N2 stage, 
depending on the T stage of the tumor (7). The 
evaluation of the lymph node involvement begins 
preoperatively, but continues intraoperatively and with 
postoperative histologic examination. 
 
Discussion 
Pretherapeutic evaluation of the lymph node status 
in rectal cancer  
Preoperative evaluation of lymph node status in 
rectal cancer is based on imaging modalities, clinical 
examination having limited value. The main imaging 
modalities used for TNM staging in rectal cancer are 
endoscopic rectal ultrasound (ERUS), magnetic 
resonance imaging (MRI), computed tomography (CT), 
and Positron emission tomography-computed 
tomography (PET-CT). The accuracy of the abdominal 
CT in predicting the N stage is low, between 53%-73%, 
with an important percentage of cases overstaged (16%) 
or understaged (10%) and a sensitivity of 17%-33% and 
specificity of 81% (8, 9). In a randomized trial 
FoxTROT, 83% of the pN+ were radiologically 
classified as cN+, but with the same tendency of 
overstaging the N stage (10). Nevertheless, the 
abdominal CT appears to be the most frequently used 
staging modality in rectal cancer centers (55% of centers 
use abdominal CT in all cases of rectal cancer for staging 
purposes) (11). 
PET/CT manifests also a lower accuracy (60-66%), 
specificity (81-90%), and sensitivity (33%) in detecting 
lymph node invasion in colorectal cancer (8) and 
represents the least common imaging method used for 
preoperative staging of rectal cancer: only 1% of centers 
use PET/CT for preoperative staging of all rectal cancer 
cases (11). ERUS probably represents the best 
preoperative staging modality for small rectal tumors (T1 
and T2); the incidence of lymph node metastases in these 
cases varies from 14.3% to 18.4% (12). However, the 
usage of ERUS as a staging method in all rectal cancer 
cases varies from 21% to 43% in colorectal cancer 
centers (11). 
 
Figure 1. Endoscopic ultrasound in rectal cancer. 
A. A rectal adenocarcinoma invading all layers 
of the rectal wall (T3) with cleavage plane with 
the prostate and peritumoral lymphadenopathy 
B. Multiple suspected (round, hypoechogenic) 
lymph nodes in a patient with a rectal 
adenocarcinoma. 
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ERUS has a 73%-76.47% accuracy in detecting 
lymph node metastases in rectal cancer, with a sensitivity 
of 52.94%-77% and a specificity of 70%-84.31% (13, 
14). The value of ERUS in the N staging of rectal cancer 
is influenced by the experience of the examiner and the 
tumor morphology (i.e., it is lower in large-stenosing 
tumors that do not allow the probe to pass through the 
lumen). Also, it may be difficult to differentiate 
malignant lymph nodes from benign ones, the malignant 
appearance being suggested by the lymph node 
morphology and size: round, hypoechogenic lymph 
nodes, larger than 3-5 mm present a higher probability of 
malignant colonization. 
In order to improve the N staging, other modalities 
may be used in association, such as fine-needle 
aspiration cytology of the detected lymph nodes which 
may increase the accuracy of the ERUS in detecting 
colonized lymph nodes by up to 90%, with a sensitivity 
of 87%, and a specificity of 100% (15). Also, using 3-D 
endoscopic ultrasound, the accuracy of the nodal 
detection may increase up to 87.3%, specificity up to 
91.4%, and sensitivity up to 79.1% (16).   
Endoscopic Ultrasound Elastography (EUS 
elastography) has proven to be a reliable method for 
differentiating rectal adenomas from adenocarcinomas 
(17), with an accuracy of 0.94, a sensitivity of 0.96, and 
a specificity of 0.86. Furthermore, in differentiating 
benign from malignant lymph nodes, elastography 
presented a sensitivity of 70.2-85% and a specificity of 
91-100%, depending on the elastography score, with the 
lowest sensitivity (60%) and specificity (31.5%) for a 
score 2 (18, 19). However, the role of ERUS 
elastography in the evaluation of the lymph nodes in 
rectal cancer remains to be demonstrated. 
 
Figure 2. ERUS elastography: perirectal enlarged 
lymph nodes with elastography hard aspect (blue) 
in a patient with a rectal adenocarcinoma. 
MRI is used for all cases of rectal cancer staging by 
20-42% of the colorectal cancer centers (11). The 
accuracy of MRI in detecting lymph node metastases in 
rectal cancer varies from 68.49%-74.5% to 92%, with 
61.76%-85.71% sensitivity and 57.78%-80.88% 
specificity, similar to the ERUS (13, 20, 21). However, 
the MRI presents the same problems of differentiating 
between benign enlarged lymph nodes and malignant 
lymph nodes, the diagnosis being based on the same 
criteria as for ERUS (lymph nodes morphology and size) 
(21).  
  
Figure 3. MRI in rectal cancer: multiple suspected 
lymph nodes in the presacral region (A) and on the 
left pelvic sidewall region (B). 
Pre and post-neoadjuvant treatment evaluation of the 
lymph nodes represents an important objective and may 
be realized using ERUS, MRI, or both as complementary 
methods. Neoadjuvant chemoradiotherapy decreases the 
tumoral volume and may also determine a downstaging, 
thus becoming very important in evaluating the treatment 
response; the lymph nodes post-neoadjuvant treatment 
downstaging may be as high as 72.2% (22). The pre-
neoadjuvant treatment accuracy of the lymph node 
detection using ERUS was 56% but increases in the post-
neoadjuvant setting to 74%, while the MRI accuracy was 
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the same in pre and post-neoadjuvant settings (74%), as 
reported by Swartling et al. These authors concluded that 
the staging accuracy was improved using the 
combination of the ERUS and MRI (23). 
Intraoperative evaluation of the lymph nodes; 
extended lymphadenectomy in rectal cancer 
Intraoperative evaluation of the lymph nodes in 
rectal cancer raises two major points of contention: the 
attitude over the potentially involved lymph nodes 
located at a distance from the rectum, and the importance 
of the lateral lymph nodes dissection. 
Regarding the potential involvement of lymph nodes 
located outside the regular area of drainage of a rectal 
cancer, the recommendation is to follow the oncologic 
principle of biopsy and, if possible, removal of all the 
enlarged lymph nodes in order to reduce the tumoral 
volume and correctly stage the case.  
A special consideration must be accorded to lymph 
nodes located at the origin of the inferior mesenteric 
vascular package: ligation and section of the inferior 
mesenteric artery and vein at their origin is not 
mandatory, many surgeons performing it below the left 
colic artery origin without any negative influence on the 
distant survival or recurrence rate. Obviously, the 
presence of an enlarged lymph node at this level requires 
ligation of the inferior mesenteric artery at its origin and 
removal of the lymph nodes. 
Regarding perirectal (intra-mesorectal) lymph nodes, 
these may be palpated in some cases but intraoperative 
biopsy is not recommended, requiring sectioning of the 
mesorectal fascia which may compromise the oncologic 
results. Quirke et al. have demonstrated that the plane of 
surgery achieved during rectal resection for cancer has 
an important influence on the local recurrence rate and 
distant survival: a 3-year 4% local recurrence rate if the 
mesorectal plane was achieved, compared to 13% if the 
muscularis propria plane was entered during surgery, 
respectively a 79% 3-year disease-free survival rate, if 
the mesorectal plane was achieved, compared to 70%-
75% if the mesorectal plane was compromised during 
surgery (24). 
Probably the most debatable point relates to the 
extended lateral (pelvic) lymph node dissection. Western 
surgeons do not perform and do not routinely 
recommend lateral lymph node dissection in rectal 
cancer, considering metastases in these lymph nodes as 
systemic spread of the disease; consequently, they are 
treated with chemoradiotherapy. Moreover, the 
MERCURY study group has found through MRI an 
incidence of 11.7% suspicious lateral lymph nodes, but 
the 5-year disease free survival was influenced only in 
the cases receiving primary surgery (42% 5-year DFS) 
and not in the group receiving neoadjuvant treatment, 
which supports the above opinion (25). 
Extended lateral lymph node dissection is more 
common among Eastern surgeons, especially in Japan. 
The incidence of lateral lymph node metastases varies 
from 10% to 25% of the cases (26-28) (11% in the study 
of Dong et al., 14.6% in Wu et al., and 17% in the series 
of reports by Ueno et al.) (26, 27, 29), but the presence 
of micrometastases was demonstrated in another 4% of 
the cases where the positivity of the lymph node was not 
suspected after initial histologic evaluation (30). 
The risk of lateral lymph node involvement 
increases in low rectal cancers (below peritoneal 
reflection) with the T stage, circumferential rectal wall 
involvement, tumor size >5 cm, advanced tumor 
infiltration and poor differentiation (26, 27), and also 
with the presence of the positive mesorectal lymph nodes 
(28), but this is not mandatory since Ueno et al. have 
found that 24% of the cases (10 out of 41 cases) with 
invasion in the lateral pelvic lymph nodes had no 
invasion in the mesorectal lymph nodes (29). 
Extended lymph nodes resection, including the 
origin of the inferior mesenteric artery and pelvic 
sidewall dissection, has been associated with an 
improved 5-year survival for all stages (overall 68% 5-
year survival rate for extended lymphadenectomy vs 
42.9% for conventional resection) as reported in Dong et 
al. (26). In a retrospective study, Shirouzu et al. found 
that TME associated with lateral lymph node dissection 
produced better results than conventional surgery, but 
only in Dukes C stage: 13.3%-16.7% local recurrence 
rate vs 25% for conventional surgery (31). Wu et al. have 
also demonstrated that the presence of lateral lymph 
node metastasis is associated with a significantly 
increased risk of local recurrence (64.3%) compared with 
patients without lateral lymph node metastases (11%), 
and a significantly lower median survival rate (38 ± 6.7 
months vs 80.9±2.1 months) (27). Ueno et al. have also 
found a lower 5-year survival rate in cases with lateral 
lymph node involvement, only 32%-42%, and an 
increased risk of local recurrence (56.8%), in cases 
without distant metastases (28, 29). 
The main selection criteria for lateral pelvic 
dissection in rectal cancer are: advanced rectal cancers 
(T3 and resectable T4 and some advanced T2 cancers, 
stage III on the TME specimen), located below the 
peritoneal reflection, on a suitable patient, without 
distant or peritoneal metastases (26, 32). Wu et al. 
recommend lateral lymphadenectomy for tumors larger 
than 5 cm in diameter (27, 32), although Ueno et al. 
found no significant correlation between tumor diameter 
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and lateral lymph nodes invasion (29). Ueno et al. also 
found that the increased number of invaded lymph nodes 
is associated with an increased risk of lateral lymph node 
metastases (2/3 of the cases with lateral lymph node 
involvement had 4 or more positive lymph nodes), and a 
lower long-distance survival (4% for 4 or more positive 
lymph nodes compared with 75% for less than 3 
involved lymph nodes) (28, 29). 
In spite of the apparently better results of the 
extended lymph node dissection, the higher morbidity, 
especially in terms of genitourinary dysfunction, requires 
supplementary criteria for case-selection for lateral 
lymph nodes dissection.  
However, with the lateral lymph node dissection and 
autonomic nerve preservation, better results were 
obtained in terms of perioperative results (31), but results 
appear to be better in terms of urinary function and not 
so good in terms of genital impairment (33). 
The size of the pelvic lymph nodes appears to be an 
important criterion; on histopathologic analysis on a cut-
off of 8.4 mm for the long axis and 5.4 mm for the short 
axis, Ishida et al. obtained an accuracy of 71.9% (for the 
long axis) and 72.8% (for the short axis, respectively) in 
predicting the risk of lateral lymph nodes metastases 
(34). However, a more recent study demonstrated a 
lower positive predictive value of the lymph node size 
for lateral lymph nodes compared to perirectal 
(mesorectal) lymph nodes (35). 
Using the same criteria, Matsuoka et al. consider 
that an ovoid shape with transverse axis larger than 5 
mm of the lymph nodes identified on MRI represents an 
optimal criterion for lateral dissection in rectal cancer 
(36). Ueno et al. have also found that in cases with lateral 
lymph node invasion, the diameter of the lymph nodes 
was statistically larger than the diameter of the non-
invaded lateral lymph nodes (8.5±4.1 vs 6.0±2.8 mm); 
the incidence of lateral lymph nodes invasion increased 
progressively with the size of the lymph nodes from 
3.6% in cases with lymph nodes < 5 mm, up to 34% in 
cases with lymph nodes larger than 10 mm (29). Quadros 
et al. have used intraoperatively a radiotracer and a blue 
dye stain which allowed them to find with 100% 
accuracy and sensitivity in 37.1% of the cases metastatic 
lymph nodes in the retroperitoneal and lateral pelvic 
area, with an upstaging rate of 11.1% (out of which 5.5% 
were due to micrometastases identification) (32). 
In conclusion, the debate over the necessity of lateral 
pelvic lymph node dissection remains open, even if the 
meta-analysis performed by Cheng et al. found no 
significant difference in terms of 5-year survival and 
recurrence rate, but the postoperative morbidity was 
higher in cases with lateral dissection performed (37). 
Establishing clear preoperative criteria for indication of 
the lateral lymph nodes dissection remains, also, an open 
discussion. 
Pathologic evaluation: sentinel lymph node 
mapping and micrometastases significance in rectal 
cancer 
It is now well recognized that the number of the 
pathologically examined lymph nodes has a great 
influence on colorectal cancer staging, and ultimately on 
distant survival of the patients (38-40). Starting with the 
sixth edition of the AJCC staging system it was 
established that a minimum of 12 lymph nodes must be 
histologically evaluated in order to ensure an adequate N 
staging, a recommendation that was maintained in the 
subsequent seventh edition and in the current guidelines 
for rectal cancer (39, 41, 42). At this point, the 
histological examination of fewer than 12 lymph nodes is 
considered a risk for residual disease and incorrect 
downstaging and an adjuvant chemotherapy protocol 
must be employed (38-41). In spite of the 
recommendations there are many situations in which the 
minimum number of 12 lymph nodes is not reached, 
even in the most developed care systems (38, 43, 44, 45), 
negatively influencing the quality of the staging. Many 
factors influence the number of the lymph nodes 
examined on a resection specimen for rectal cancer (41, 
43, 46), out of which the neoadjuvant therapy appears to 
be a specific one (47). There are many modalities trying 
to improve the staging, including the injection of a blue 
dye in the inferior mesenteric artery (48) in order to 
identify more stained lymph nodes; NCCN guidelines for 
rectal cancer recommend, in case of fewer than 12 lymph 
nodes identified, for the pathologist to review the 
specimen in an attempt to identify more lymph nodes 
(41). Probably the most debatable method trying to 
improve the pN staging in rectal cancer remains the 
sentinel lymph node mapping; however, current 
guidelines recommend caution in interpretation of the 
results (41). 
Several methods have been used for identification of 
the SLN in rectal cancer: in vivo or ex vivo techniques, 
different staining dyers or radiotracers, even different 
techniques of pathologic evaluation (seriate sections, 
usual hematoxylin-eosine staining method, immune-
histochemistry or polymerase-chain reaction) (49-55), all 
leading to a lack of uniformity and making finding a 
common and reproducible path difficult.   
The detection rate of the SLN varies from 61.9% to 
97.8%-100%, the sensitivity 50%-58.3% to-80%- 93.7%, 
with a false negative rate of 3.84%-10.7% to 18.18%-
20%, and an upstaging rate varying from 4.76%-12.5% 
to 29%-37.5%. The results were better when the study 
included the colon and the rectum cases together (49-55). 
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As a consequence, the different detection rate, 
sensitivity, and specificity of these methods represent 
other reasons for which SLN mapping is not a method 
sufficiently good to be recommended as a guideline, 
even though most studies have demonstrated some 
degree of upstaging. The main advantage, present in 
most of these studies, is represented by the identification 
of a higher number of lymph nodes submitted to 
pathologic evaluation than conventional, non-staining 
methods (49-55). Making the decision even more 
difficult, the significance of the micrometastases and 
isolated tumor cells identified on the examined lymph 
nodes only by IHC or RT-PCR is still up for debate.  
The incidence of micrometastases varies, depending 
on the examination technique, from 25.5-30% to 54-60% 
if IHC or RT-PCR technique, respectively, is used for 
detection (56-58). 
Wang et al., have found a significant drop in the 5-
year survival rate in patients diagnosed with 
micrometastases (lymph node metastases smaller than 2 
mm, but larger than 0.2 mm) (50%-50.3% vs 92.3%), 
and the decrease of the survival rate was higher for 
micrometastases identified only by IHC; the same trend 
was noticed for the 5-year disease-free survival rate 
(47.5%-50% in the presence of micrometastases vs 
92.4% if micrometastases were not present) (56). On the 
other hand, Liefers et al., and Koyanagi et al., have found 
a large decrease in the observed 5-year survival rate from 
75% in cases without micrometastases to 36% in cases 
with RT-PCR detected micrometastases, respectively in 
the mean disease-free survival rate (61 vs 37 month) (57, 
58). On the other hand, Oh et al., have found no 
significant influence of the micrometastases or isolated 
tumor cells on disease-free survival rate and prognosis 
(59). 
As a consequence, the importance of the 
micrometastases, IHC or RT-PCR detected, remains 
controversial. On the other hand, the 7th edition of the 
AJCC staging system included as prognostic factor, at 
least for the T1-T2 tumors, the peritumoral (mesorectal) 
satellite nodules (tumor deposits), which were included 
as N1c stage if they respect the contour and form of a 
lymph node (42, 60). Tumor deposits were found in 
31.9-36.4% of the studied cases and led to an important 
stage migration between the AJCC staging systems since 
their introduction (60), with 40.2-44.2% of the cases 
becoming stage III with the TNM 7th edition. Thus, the 
role and especially the definition according to size, form 
and contour of these tumor deposits remain in debate, in 
spite of the proven negative prognostic value (60-62). 
Conclusions 
Despite important progress made in the evaluation 
and prognostic interpretation of lymph nodes in rectal 
cancer, many controversial and unresolved aspects 
remain, requiring future clarification. However, accurate 
interpretation requires better standardization than is now 
offered by current staging systems, as demonstrated by 
the present studies. 
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